Research and Clinical Trials
- Women's Interagency HIV Study
- Clinical Trials
- Microbicide Research
- Vaccine Research
- Additional Information on Research and Clinical Trials
To confront the growing problem of HIV infection and AIDS in women, the National Institute of Allergy and Infectious Diseases (NIAID) has made research on women an important part of the Institute's AIDS research program.
The Women's Interagency HIV Study, started in 1993, is designed to investigate the history and course of HIV infection in women. This nationwide study tracks 3,000 HIV positive women and 1,000 women without HIV but at high risk of getting the virus. About 80 percent of those in the study are minority women. Several findings from the study are listed below.
- Depression leads to lower T-cells and greater risk of death in HIV positive women. These findings point to depression as a risk factor for death for HIV positive people, both male and female.
- A look at HIV positive women found that vitamin A deficiency was associated with abnormal Pap smears, the first step towards cervical cancer.
- Active drug users who were HIV positive had a higher rate of death from non HIV causes. These included deaths from liver failure, murder, suicide, and overdose on illicit drugs.
Many areas of HIV/AIDS research involve clinical trials. Clinical trials are research studies designed to find out if new drugs, vaccines, or other treatments are safe and if they work. Sometimes, it can be hard for patients to learn about opportunities to take part in clinical trials. Doctors and patient advocacy groups can be great resources for patients looking for clinical trial information.
You can find out about HIV/AIDS clinical trials at the National Institutes of Health (NIH). You can also call the Vaccine Research Center of the NIH at 1-866-833-5433.
Newspapers, particularly in large cities, often carry clinical trial recruitment advertisements. A call to a nearby university medical center can also lead to information about clinical trials currently recruiting patients. If you decide to take part in a clinical study, see the CDC brochure to learn what questions you should ask. Below are three popular HIV/AIDS clinical trial groups.
- AIDS Clinical Trials Group (ACTG)
ACTG, the largest HIV clinical trials organization in the world, plays a major role in setting standards of care for HIV infection and OIs related to HIV/AIDS in the United States and the developing world.
- Pediatric AIDS Clinical Trials Group (PACTG)
PACTG evaluates treatment for HIV-infected children and teens, and for developing new approaches for understanding passing HIV from mother to child. Those most benefited by the PACTG includes underserved pregnant women, infants, children, and adolescents of diverse racial and ethnic backgrounds.
- HIV Prevention Trials Network (HPTN)
NIAID established the HPTN in July 2000 as a global research network to evaluate the safety and value of non-vaccine prevention medicines, including topical microbicides. Research through the HPTN is carried out through HIV Prevention Trials Units (HPTUs) located at 15 sites in the United States in Alabama, California, Maryland, Massachusetts, New York, North Carolina, Pennsylvania, Washington;14 sites overseas in Africa, Asia, Europe, and South America are also included.
A topical microbicide is a gel, cream, or foam that is applied vaginally to prevent STDs such as HIV. Products undergoing research may work by:
- slowing down HIV
- blocking attachment of HIV to at-risk cells
- stopping viral spread from the first cells that acquire HIV to other cells in the body
In addition to products that can be applied vaginally, the program also is researching the possibility of using microbicides to prevent passing HIV during anal sex.
NIAID supports a wide variety of topical microbicide research programs. Below are completed NIAID-supported clinical trials.
- A domestic and international Phase I study of PRO2000/5 gel, a product that slows down HIV entry into the body. PRO2000/5 gel was found to be safe. Future studies will be planned.
- A Phase I safety study of an acid-buffering product that may reduce passing of STDs, including HIV, by maintaining the natural acidity (tartness/bitterness) of the vagina in the presence of seminal fluid. HIV negative, sexually abstinent and active women using the acid-buffering product, BufferGel, did not experience any serious side effects.
- An expanded Phase II safety study of a gel containing the spermicide, nonoxynol-9 (N-9), for vaginal use. No serious safety concerns were identified.
- A Phase I safety study of an N-9 containing gel for rectal use. No serious safety concerns were identified.
- A Phase III trial of an N-9 containing vaginal film. N-9 did not provide significant protection against the passing of HIV.
Research on ways to control AIDS remains a top priority for the NIH. HIV vaccines are a key component of this research because they could work in one of several ways:
- to prevent passing
- to prevent HIV infection
- to prevent the progression of HIV to AIDS
The AIDS Vaccine Research Working Group (AVRWG), formerly known as the AIDS Vaccine Research Committee or AVRC, assists the NIH in developing research aimed at speeding up the discovery and development of an HIV/AIDS vaccine. Below are the two different types of vaccines being researched.
- Preventive vaccines are for HIV negative individuals; they are to prevent HIV infection.
- Therapeutic vaccines are for HIV positive individuals; they are to strengthen the immune system.